|By PR Newswire||
|March 11, 2014 10:00 AM EDT||
LONDON, March 11, 2014 /PRNewswire/ --
Antibacterials - new analysis showing business trends, R&D, and revenue forecasts
What is the future of medicines treating bacterial infections? For those drugs you get new sales predictions, also exploring research and development. Those treatments hold high potentials. There you assess results, progress, therapies, and opportunities.
Knowledge facilitates success. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. There you stay ahead in data on microbial diseases, finding commercial prospects to benefit your influence.
Read on to explore antibiotics for human healthcare, seeing how high sales can go.
Forecasts to 2024 and other analyses explain and predict that antimicrobials market
Why miss data you need? Why struggle to find it, or fall behind? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find recent results, growth rates, market shares, and discussions.
Also you see the potential of research and development. That study gives 126 tables, 102 charts, and interviews with three companies.
There you assess the future of antibacterials, hearing how patients, doctors, and pharma companies can benefit. You stay ahead, then, finding where money lies, assessing the most lucrative selling prospects.
And the following sections show how that new investigation helps your research, analyses and decisions. See there how you could benefit your authority and save time, staying ahead.
Sales predictions for the world antibiotics market and submarkets
What is that biomedical industry's potential? What are the secrets of its progress? Discover in our report overall world revenue to 2024 for those bacteria-treating agents.
Also find individual revenue predictions to 2024 for six therapeutic submarkets at world level:
• Other treatments for bacterial infections.
There you explore prospects from 2014, hearing where you could profit from novel agents and generic drugs (generics). Investigate competition, developments, and rising sales.
That study also predicts and discusses leading medicines' sales potentials
To see an exec summary of this report please email Sara Peerun on [email protected] .
Revenue predictions for leading and expected products
How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 43 products - marketed agents and drugs awaiting launch.
You assess top products, including these:
• Generic amoxicillin
There you find medicines and years with highest predicted sales. Also you examine competitors and get an understanding of recent challenges, trends, and outlooks.
For that overall market, the report also shows geographical revenue predictions.
National markets - what are the demands for antibacterial therapies?
In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2014 to 2024. See where and how.
Our analyses show you individual revenue forecasts to 2024 for a regional block and 12 national markets:
• United States (US)
• European Union (EU) - also with separate forecasts for France, Germany, the UK, Italy, and Spain (EU5 countries)
• South Korea
• The BRIC nations - Brazil, Russia, India, and China.
For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for fighting bacterial infections, also assessing the expected financial gains.
And what events change that industry? Our work shows you, discussing trends, challenges and opportunities.
Market forces and issues - what affects antibiotic developers, producers and sellers?
The report shows you issues and events affecting that industry and market from 2014, including these:
• Antibacterial drug consumption statistics at national level
• Incidences of urinary tract, skin, and respiratory tract infections from bacteria
• Generic competition for leading brands - effects of patent expiries
• Prescription control to reduce bacterial resistance, including that of methicillin-resistant S. aureus (MRSA)
• Encouraging antibiotic drug discovery and development - push and pull incentives, inc. public-private collaborations.
And you explore these influences, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other new drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies.
Discover what the future holds. There you explore political, economic, social, and technological questions. See, too, how R&D lets companies benefit patients.
There you find what stimulates and restrains players in that sector, and affects its results.
To see an exec summary of this report please email Sara Peerun on [email protected]
Analysis of top companies and potential for market growth - what revenue is possible?
From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from bacteria-treating drugs.
So what happens next? Our study predicts that world market will reach $42.75bn in 2018, with further expansion to 2024.
That work also explores activities and potentials of these companies, among others:
• GlaxoSmithKline (GSK)
• Merck & Co.
• Cubist Pharmaceuticals
• Daiichi Sankyo.
R&D in that industry holds strengths, and from 2014 opportunity arises. Patients, payers, and companies will benefit. Discover what is possible.
And you will be able to see how that market can perform, staying ahead in knowledge and benefiting your reputation for commercial insight.
Ways Antibacterial Drugs: World Industry and Market Prospects 2014-2024 helps you
In particular, that new investigation gives you this information:
• Revenues there to 2024 at world level, for 6 submarkets, and 43 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.
Knowledge found nowhere else, helping your searches, analyses, and planning
Our study gives independent data. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.
With that original research and analysis you are less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort. And also help your plans, decisions, influence, and competing.
The new report shows commercial potentials of medicines for human infective diseases. There you explore trends and R&D, and investigate future sales. So avoid missing out - please order now.
Companies Listed in this report:
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA)
Brazilian National Health Surveillance Agency
Centers for Disease Control and Prevention (CDC)
Chinese Ministry of Health
Dr. Reddy's Laboratories
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Fitch Ratings Agency
Food and Drug Administration (US FDA)
Hi Tech Pharma
Indian Ministry of Health and Family Welfare
Itochu Chemical Frontier
Japanese Ministry of Health Labor and Welfare
Johns Hopkins University School of Medicine
Johnson & Johnson
Medicines and Healthcare Products Regulatory Agency
Meiji Seika Pharma
Merck & Co.
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Institute for Health and Clinical Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Procter & Gamble
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Sistema Nacional de Gerenciamento de Produtos Controlados
Teva Pharmaceutical Industries
The Medicines Company
University of Leicester
University of Michigan
US Department of Health
World Health Organization (WHO)
Zhejiang Medicine Company
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel : +44(0)20-7336-6100
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Jul. 30, 2016 11:30 PM EDT Reads: 1,321
CenturyLink has announced that application server solutions from GENBAND are now available as part of CenturyLink’s Networx contracts. The General Services Administration (GSA)’s Networx program includes the largest telecommunications contract vehicles ever awarded by the federal government. CenturyLink recently secured an extension through spring 2020 of its offerings available to federal government agencies via GSA’s Networx Universal and Enterprise contracts. GENBAND’s EXPERiUS™ Application...
Jul. 30, 2016 10:30 PM EDT Reads: 1,939
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 30, 2016 09:45 PM EDT Reads: 1,494
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Jul. 30, 2016 09:45 PM EDT Reads: 1,317
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 30, 2016 09:30 PM EDT Reads: 1,528
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Jul. 30, 2016 07:30 PM EDT Reads: 1,762
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Jul. 30, 2016 07:30 PM EDT Reads: 1,318
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
Jul. 30, 2016 07:00 PM EDT Reads: 2,775
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Jul. 30, 2016 05:00 PM EDT Reads: 1,307
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
Jul. 30, 2016 04:30 PM EDT Reads: 584
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Jul. 30, 2016 04:30 PM EDT Reads: 1,124
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 30, 2016 04:30 PM EDT Reads: 2,283
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Jul. 30, 2016 04:15 PM EDT Reads: 652
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Jul. 30, 2016 02:30 PM EDT Reads: 1,074
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Jul. 30, 2016 02:00 PM EDT Reads: 541